Ford Motor Company vs Incyte Corporation — how do they compare? Ford Motor Company trades at $13.85 (market cap $55.75B), while Incyte Corporation trades at $120.56 (market cap $24.54B). The key difference: Ford Motor Company is far larger — about 2.3× Incyte Corporation's market cap, and Ford Motor Company pays a 4.29% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| F | INCY | |
|---|---|---|
Market Cap | $55.75B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $129.93 |
52-Week Low | $11.21 | $81.61 |
Enterprise Value | $187.71B | $20.04B |
Dividend Yield | 4.29% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $14.015, up 0.25% on the day, with a bearish technical signal and mixed earnings history including a recent Q3 2026 miss. The company reported a net loss of $8.18 billion for 2025, with negative profit margins, but maintains strong operating cash flow of $21.28 billion. Recent news highlights the upcoming affordable Fathom EV truck priced around $28,000, targeting market share gains amid high vehicle prices.
The outlook is cautious; while analyst consensus is a Buy with a $16.18 price target, fundamental weaknesses like negative ROE and net income margin pose risks. The EV transition and competitive pressures are key challenges, but the dividend yield and cash flow stability offer some investor appeal. Execution on new models like the Fathom is critical for a turnaround.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Trailing returns across standard periods
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →